Please upgrade your browser.
Immunotherapy continues to evolve as a treatment option for various cancers; however, men may see more benefit from it more than women, according to a study published in The Lancet Oncology.
Robotic-assisted procedures have now become ubiquitous in some kinds of surgeries. What once was seen as a technological marvel is commonplace in many hospitals. But studies in recent years have shown robotic surgery performs no better than traditional surgery - even though it comes at a steeper cost to the overall health-care system.
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma (RCC). One of the biggest unanswered questions in the frontline setting of metastatic RCC is the role of PD-L1. Pal says that there is more to the PD-L1 story, particularly considering the findings of the CheckMate-214 trial. There was a clear difference in clinical outcomes for patients who were PD-L1–positive versus PD-L1–negative, Pal explains. Whether that is clinically applicable is not established.
Bristol-Myers Squibb Company BMY announced that the FDA accepted its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo for the indication first-line advanced non-small cell lung cancer (NSCLC) in patients with tumor mutational burden (TMB) ≥10 mutations per megabase (mut/Mb). The FDA set an action date of Feb 20, 2019.
Ipsen, a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center today announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson’s Institute for Applied Cancer Science (IACS).
Emergency department visits, including those that resulted in hospital admissions, grew an average 4 percent every year from 2010 to 2016.
KEYNOTE-427 is a single-arm, open-label, non-randomized, multi-cohort, Phase 2 study evaluating the safety and efficacy of KEYTRUDA as monotherapy in patients with advanced RCC who have not received prior systemic therapy.
To evaluate trends in the use of partial nephrectomy in the United States, researchers collected information about more than 48,000 patients with non-metastatic kidney cancer treated between 1998 and 2007.
The Kidney Cancer Association has announced the winners of its annual Young Investigator Award (YIA). The award provides funding to promising doctors to pursue careers in kidney cancer research.
The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib 50 mg daily for 4 weeks followed by 2 weeks off every cycle.
|Powered by NeonCRM|